BUILDING THE FUTURE: INA-RESPOND IN 2025

By: Aaron Neal

Dr. Aaron Neal
NIAID Lead for the Indonesia Research Partnership

INA-RESPOND has much to celebrate over the past year, and much to be excited for in 2025. Highlights from 2024 include the completion of the InVITE study, presentations at the annual Re-PORT tuberculosis (TB) meeting in Brazil, and the acceptance of key publications from HIV study (INA-PROACTIVE) and TB study (TRIPOD). Despite the successes from last year and the many years before, it is important to acknowledge the uncertainty that has hovered around the future direction of the partnership. This year will bring substantial changes to many elements of INA-RESPOND, but I remain optimistic and excited for these new opportunities in 2025.

Beginning with the establishment of Indonesia National Research and Innovation Agency (BRIN) in 2019 and continuing through the Ministry of H e a l t h ( M o H ) d e c r e e H K . 0 1 . 0 7 /MENKES/1458/2023 in 2023, the organization of clinical research in the MoH has shifted significantly. INA-RESPOND remains a government-to-government partnership between the MoH and US-NIAID, so we must adapt to this new landscape and ensure that our structure and activities align with MoH expectations. Health Minister Budi Gunadi Sadikin, Director General for Health Ser-vices (Yankes) Azhar Jaya, and Dr. Cliff Lane reached the decision to relocate INA-RESPOND from the Health Policy Agency (BKPK) to RSPI Sulianti Saroso (RSPI SS) as a joint Clinical Re-search Unit (CRU) focused on infectious diseases. This is a significant change in the MoH governing partner, which began as NIHRD, morphed into BKPK, and is now transitioning to Yankes. With Yankes as the new governing partner and RSPI SS as the new operational partner, this will mean physically relocating the Secretariat and staff to RSPI SS, integrating the organization of the partnership into the existing CRU organization, and mapping out ways for INA-RESPOND and RSPI SS to work both independently and in collaboration with each other. This is no simple task, and those who were with INA-RESPOND in the early days will understand the challenges that come with establishing a new partnership. We have already begun planning the transition of INA-RESPOND to Yankes, and DG Azhar Jaya visited the NIH on 4-5 December to hold the first Executive Steering Committee meeting with Dr. Lane and others from Yankes, RSPI SS, INA-RESPOND, and NIAID. We anticipate additional meetings in Jakarta in early 2025 to finalize elements of the transition.

Though the Secretariat is expected to relocate, its structure, function, and capacity should remain the same. In fact, I expect that there will be greater opportunities for Secretariat staff to share scientific knowledge and operational expertise with MoH CRUs and the INA-CRC, ultimately contributing to enhanced research capacity across the MoH. The INA Reference Laboratory remains a strong component of INA-RESPOND, and I do not anticipate any significant changes to the lab under the new partner. Like the Secretariat, I expect that there will be new opportunities for lab staff to strengthen lab capacity at RSPI SS and other MoH labs through trainings and technical exchanges.
The current INA-RESPOND sites will likely be the most affected by the changes coming to the partnership. Under the new MoH system of CRUs, it makes the most sense for INA-RESPOND to work directly with the newly established CRUs as studies require. This would be different from the current model of core sites staffed by INA-RESPOND re-search assistants. The logistics of working with CRUs still need to be discussed in detail, but it seems that CRUs now fulfil the role that INA-RESPOND research units once occupied. The final element that will see changes in 2025 is the high-level governance of the partnership. The relocation of INA-RESPOND to RSPI SS brings the expectation of merging organizational and leader-ship structures. A new governance model has been approved by DG Azhar Jaya and Dr. Lane, and once the remaining elements of the transition have been finalized, we anticipate hosting a partnership-wide meeting to celebrate the past success of INA-RESPOND and kick-off the future of the partnership under Yankes and RSPI SS.

I am most excited about the scientific possibilities for INA-RESPOND in 2025. As we all know, the completion of the InVITE study marked the end of active INA-RESPOND studies. During this down-time, Secretariat and NIAID staff have been seek-ing new research and funding opportunities that would begin this year. Many of the MoH and global infectious disease priorities are the same as in past years, i.e. HIV/AIDS, TB, COVID-19, and antimicrobial resistance, but we have also seen renewed interest in longstanding disease threats like Dengue and Zika virus infections. I anticipate opportunities to collaborate with RSPI SS investi-gators on TB research and international investiga-tors on dengue research, including a potential phase III global study on immunomodulatory drugs for severe dengue. These potential studies and others will be excellent opportunities to showcase the growth of INA-RESPOND as the partnership pursues more high-impact interventional studies rather than large-scale surveillance studies.

INA-RESPOND is adapting to significant changes in the Ministry of Health. This will be the most substantial reconfiguration of the partnership since it was established in 2010, and I am excited for future opportunities to conduct important infectious disease research with our new partners Yankes and RSPI Sulianti Saroso.

Leave a reply